TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04990609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)
Description: Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) consists of the application of an alternating current with a frequency of 350-500 kilohertz (kHz) to the target tissue via a special electrode located at the tip of an echoendoscope. The alternating current causes the vibratory movement of ionic particles in the abutting and adjoining tissue and results in the generation of heat. However, RFA induces not only local disruption of the tumor by heat, but it also produces localized coagulation necrosis of the tumor; which induces the release of large amounts of cellular debris. This cellular debris represents a source of tumor antigens that can trigger a host adaptive immune response against the tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy (NAC)
Description: The NAC regimen will be determined clinically by the participant's physician \[possible regimens are either mFOLFIRINOX or Gemcitabine Nab-Paclitaxel +/- Cisplatin (GemAbraxane)\].
Study: NCT04400149

Intervention type: DIAGNOSTIC_TEST
Intervention: amniocentesis
Description: amniocentesis will be performed to the pregnant women at 16-20 weeks who had a high-risk antenatal test. Furthermore, these women also give a blood sample (at 16-20 weeks) to compare the amniotic fluid and serum progesterone levels in association with pregnancy outcomes. We perform amniocentesis to evaluate genetic disorders in pregnant women who had his risk in the antenal test.

Intervention type: DIAGNOSTIC_TEST
Intervention: amniocentesis
Description: amniocentesis will be performed to the pregnant women at 16-20 weeks who had a high-risk antenatal test. Furthermore, these women also give a blood sample (at 16-20 weeks) to compare the amniotic fluid and serum progesterone levels in association with pregnancy outcomes. We perform amniocentesis to evaluate genetic disorders in pregnant women who had his risk in the antenal test.
Study: NCT05234268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Cervical Traction
Description: Time: 20 minutes Duration: thrice a week for 4 weeks.~Position:~The patient is in supine lying. The head and neck of patient are held in the hands of the practitioner, and then a gentle traction of a pulling force is applied. Intermittent periods of traction can be applied, holding each position for about 10 seconds. Traction is usually applied at about 20-30 degrees of neck flexion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Accessory Intervertebral Movements
Description: Time: 20 minutes Duration: thrice a week for 4 weeks~Position:~Patient lying in prone. Therapist stands to side of patient placing their pisiform/ulnar surface of hand over the selected spinous process (SP) with their wrist in full extension.~Other hand placed on top of hand to reinforce. Therapist's shoulders should be directly above the SP with elbows slightly bent. Therapist uses their body weight to apply a PA force to the selected SP by leaning their body over their arms and performing rocking movements to provide oscillatory movements of the vertebra.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Strength Training
Description: Time: 20 minutes Duration: thrice a week for 4 weeks. The progression of exercises will be done using different colors of Thera-band indicating varied resistance. (A) Resistive lateral flexion of uninvolved side.~Position:~The patient is in sitting position. By the help of thera-band patient will actively flex the neck against resistance on the uninvolved side.
Study: NCT04613440

Intervention type: OTHER
Group type: OTHER
Intervention: Family Letter (Standard of Care)
Description: The family letter is given to probands in the standard of care arm and provides information on the familial mutation and serves to encourage first degree relatives to complete genetic testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: The educational video is provided by the clinical genetic testing laboratory and explains the importance and implications of genetic testing. This educational video is shared with first degree relatives in the intervention arm

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Video
Description: The educational video is provided by the clinical genetic testing laboratory and explains the importance and implications of genetic testing. This educational video is shared with first degree relatives in the intervention arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailed Saliva Kit for Genetic Testing
Description: The FDR's email will be sent to the genetic testing lab, Invitae, which will allow them to log on to the online portal, create a unique account, and order a genetic testing saliva kit free of charge. The FDR will receive the kit and instructions in the mail. The FDR will collect the saliva sample and send the sample back to the genetic testing laboratory.

Intervention type: OTHER
Group type: OTHER
Intervention: Mailed Saliva Kit for Genetic Testing
Description: The FDR's email will be sent to the genetic testing lab, Invitae, which will allow them to log on to the online portal, create a unique account, and order a genetic testing saliva kit free of charge. The FDR will receive the kit and instructions in the mail. The FDR will collect the saliva sample and send the sample back to the genetic testing laboratory.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: The FDR's will be contacted and receive post genetic testing phone counseling

Intervention type: OTHER
Group type: OTHER
Intervention: Telephone Counseling
Description: The FDR's will be contacted and receive post genetic testing phone counseling
Study: NCT05709912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE Application
Description: Self-administered, psychosocial mobile application comprised of 5 learning modules.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Meeting with transplant social worker prior to HCT, consistent with standard-of-care.
Study: NCT06071546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAIA
Description: MAIA is a visual field testing device combining visual field tests, fixation loss correction by a real-time retinal tracker and confocal TrueColor fundus imaging (P/N AHMACME001)
Study: NCT06223308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0028
Description: Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0028 via intravenous infusion. HB0028 IV every 3 weeks (q3w).
Study: NCT05552742

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative rehabilitation
Description: The conservative rehabilitation program includes a patient-specific conservative exercise program comprising exercises that strengthen the paralyzed side, increase joint range of motion and strengthen muscles, stretch spastic muscles, and ensure balance rehabilitation that enhances balance performance and coordination. The patients in both groups received conservative rehabilitation program for 8 weeks, 4 days a week for 1 h.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative rehabilitation
Description: The conservative rehabilitation program includes a patient-specific conservative exercise program comprising exercises that strengthen the paralyzed side, increase joint range of motion and strengthen muscles, stretch spastic muscles, and ensure balance rehabilitation that enhances balance performance and coordination. The patients in both groups received conservative rehabilitation program for 8 weeks, 4 days a week for 1 h.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Balance Training
Description: Virtual balance training program using the Thera-Trainer Balo device was applied 4 times a week for a total of 8 weeks, and each session lasted for 20 min. The center of mass of each patient was determined using sensors and displayed on the screen. The patients were encouraged to move their mass by swiping in all directions via the apple picking game displayed on the screen
Study: NCT05361135

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Enhanced imaging with PET/CT
Study: NCT05885061

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulation turned on (suggestions: off)
Description: Spinal cord stimulation turned on with verbal suggestions of treatment off

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spinal cord stimulation turned off (suggestions: on)
Description: Spinal cord stimulation turned off with verbal suggestions of treatment on

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulation turned on with suggestions (suggestions on)
Description: Spinal cord stimulation turned on with verbal suggestions of treatment on
Study: NCT05269953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active stimulation
Description: Participants assigned to the active stimulation arm will receive rhythmic MNS 2 minutes on and 1 minute off for 15 minutes. The strength of the stimulation will be set to 120% the intensity needed to produce a visible contraction within the thenar muscle.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Participants assigned to the sham stimulation arm will receive rhythmic MNS 2 minutes on and 1 minute off for 15 minutes. The strength of the stimulation will be set to 50% the intensity needed to produce a visible contraction within the thenar muscle.
Study: NCT05105776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galvanic stimulation
Description: Galvanic stimulation during physiotherapy sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galvanic stimulation
Description: Galvanic stimulation during physiotherapy sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galvanic stimulation
Description: Galvanic stimulation during physiotherapy sessions
Study: NCT05350046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ear-worn prototype devices
Description: Hearing instrument including sensors to track movement and estimations of biological information.
Study: NCT04922177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect ceramic restoration
Description: Indirect ceramic restoration using an optical impression.
Study: NCT04875572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analgesia Nociception Index (ANI) Monitor
Description: The ANI monitor produces an objective measure of parasympathetic tone through non-invasive electrodes placed on the patient's chest. The patient's standard of care is not affected, and the anesthetist is blinded to the monitor, so as not to affect their anesthetic practice.
Study: NCT05098366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 0.1mg/kg (max 5mg) of IV furosemide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 20mL/kg (max 1000mL) normal saline bolus plus a normal saline flush
Study: NCT05469620

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal
Description: Either a meal kit low in sodium, potassium, and phosphorus; or a meal kit low in sodium only is provided based on predefined logic. Meal kits are delivered in bulk twice a week, meant to replace one meal a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal
Description: Either a meal kit low in sodium, potassium, and phosphorus; or a meal kit low in sodium only is provided based on predefined logic. Meal kits are delivered in bulk twice a week, meant to replace one meal a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Leaflet or video education materials on seven nutrition-related topics are provided, based on predefined logic. Materials are sent throughout the week, via SMS links.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Leaflet or video education materials on seven nutrition-related topics are provided, based on predefined logic. Materials are sent throughout the week, via SMS links.
Study: NCT06015919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dash diet
Description: * Group (A): It will include 15 post-menopausal women who will be treated by DASH diet and anti-hypertensive drugs.~* Group (B): It will include 15 post-menopausal women who will be treated by acupuncture and anti-hypertensive drugs.~* Group (C): It will include 15 post-menopausal women who will be treated by DASH diet, acupuncture and anti-hypertensive drugs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: acupuncture
Study: NCT04922177

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct restoration
Description: Restoration using a Glass Ionomer Cement
Study: NCT05116826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: 500 mg Twice Daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: 500 mg Twice Daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: 500 mg Twice Daily for 7 days
Study: NCT05787743

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial cream with 2% palm tocotrienols extract
Description: Apply on the face twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Base cream
Description: Apply on the face twice a day
Study: NCT05186051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYIL1 capsule
Description: NLRP3 inflammasome inhibitor
Study: NCT05122377

Intervention type: DRUG
Intervention: 3M GnRHa
Description: This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).

Intervention type: DRUG
Intervention: 1M GnRHa
Description: This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).
Study: NCT05977101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray
Description: Patients who met the inclusion and exclusion criteria were randomly assigned to one of three different cohorts. Subjects in each cohort were randomly assigned in a ratio of 5:1 to two parallel dosing groups, one of which served as the control group. Each cohort was given either an experimental drug or a placebo nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose, and left nasal swabs and throat swabs were collected for immunotoxicity and drug concentration testing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient
Description: Patients who met the inclusion and exclusion criteria were randomly assigned to one of three different cohorts. Subjects in each cohort were randomly assigned in a ratio of 5:1 to two parallel dosing groups, one of which served as the control group. Each cohort was given either an experimental drug or a placebo nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose, and left nasal swabs and throat swabs were collected for immunotoxicity and drug concentration testing.
Study: NCT04910581

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Single 30-minutes session of 1Hz rTMS applied over the left laryngeal motor cortex

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Description: Single 30-minutes session of sham stimulation applied over the left laryngeal motor cortex
Study: NCT05784402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide J
Description: Participants will receive oral semglutide J at dose level 1 and 3 in treatment sequence A and C; and at dose level 2 and 4 in treatment sequence B and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide J
Description: Participants will receive oral semglutide J at dose level 1 and 3 in treatment sequence A and C; and at dose level 2 and 4 in treatment sequence B and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide J
Description: Participants will receive oral semglutide J at dose level 1 and 3 in treatment sequence A and C; and at dose level 2 and 4 in treatment sequence B and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide J
Description: Participants will receive oral semglutide J at dose level 1 and 3 in treatment sequence A and C; and at dose level 2 and 4 in treatment sequence B and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide C
Description: Participants will receive oral semglutide C in treatment sequence A and B; and at semglutide C at 2x dose level in treatment sequence C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide C
Description: Participants will receive oral semglutide C in treatment sequence A and B; and at semglutide C at 2x dose level in treatment sequence C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide C
Description: Participants will receive oral semglutide C in treatment sequence A and B; and at semglutide C at 2x dose level in treatment sequence C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide C
Description: Participants will receive oral semglutide C in treatment sequence A and B; and at semglutide C at 2x dose level in treatment sequence C and D.
Study: NCT04954417

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiological scanning
Description: The collected specimens subject to normalized Micro-CT and MSCT image acquisition, image reconstruction using standard algorithms, and bone structure observation using bone algorithms to obtain high-quality, standardized axial images.

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiological scanning
Description: The collected specimens subject to normalized Micro-CT and MSCT image acquisition, image reconstruction using standard algorithms, and bone structure observation using bone algorithms to obtain high-quality, standardized axial images.

Intervention type: OTHER
Intervention: Deep learning
Description: We will use a conditional generation adversarial network-based image mapping technique to train the mapping model between MSCT images and Micro-CT images, find the correspondence between the image information contained in each of MSCT and Micro-CT, and finally obtain high-resolution micro-CT-like images.

Intervention type: PROCEDURE
Intervention: Bio-mechanical testing
Description: we will cut a standardized cubic sample from the vertebral cancellous bone , obtain the bio-mechanical performance index of this cancellous bone sample by mechanical experiments, and analyze the correlation between bone structure of Micro-CT-like images and bio-mechanical index.
Study: NCT05320510

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Se-yeast
Description: The participants will be asked to take Se-yeast tablet. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will be asked to take placebo-yeast tablet. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Study: NCT06018662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A medication management mobile application
Description: A mobile application to select the most appropriate drugs for anesthetics, antimicrobials and analgesics, in addition to dose calculations
Study: NCT05702385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials for a new diagnostic test
Description: These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials for a new diagnostic test
Description: These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
Study: NCT05029453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: In experimental group, the drug used with apatinib and chemotherapy.
Study: NCT06350253

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic cart
Description: RMR measurement via metabolic cart

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic cart
Description: RMR measurement via metabolic cart

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic cart
Description: RMR measurement via metabolic cart

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic cart
Description: RMR measurement via metabolic cart

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic cart
Description: RMR measurement via metabolic cart

Intervention type: DIAGNOSTIC_TEST
Intervention: MedGem
Description: RMR measurement via MedGem

Intervention type: DIAGNOSTIC_TEST
Intervention: MedGem
Description: RMR measurement via MedGem

Intervention type: DIAGNOSTIC_TEST
Intervention: MedGem
Description: RMR measurement via MedGem

Intervention type: DIAGNOSTIC_TEST
Intervention: MedGem
Description: RMR measurement via MedGem

Intervention type: DIAGNOSTIC_TEST
Intervention: MedGem
Description: RMR measurement via MedGem

Intervention type: DIAGNOSTIC_TEST
Intervention: BIA
Description: RMR estimation from BIA analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: BIA
Description: RMR estimation from BIA analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: BIA
Description: RMR estimation from BIA analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: BIA
Description: RMR estimation from BIA analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: BIA
Description: RMR estimation from BIA analysis
Study: NCT06379542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8
Description: 40 mg/day or 80 mg/day for 7-14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets/day for 7-14 days
Study: NCT06530355

Intervention type: OTHER
Intervention: The same evaluation methods were used for both groups.
Description: No treatment applied to participants and same evaluation methods used in all athletes.

Intervention type: OTHER
Intervention: The same evaluation methods were used for both groups.
Description: No treatment applied to participants and same evaluation methods used in all athletes.